ID   ARD
AC   CVCL_XD83
SY   ard-1
DR   CCRID; 1101HUM-PUMC000681
DR   GEO; GSM2774119
DR   GEO; GSM2774122
DR   GEO; GSM2774124
DR   GEO; GSM2774126
DR   Wikidata; Q93325829
RX   CelloPub=CLPUB00604;
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=8427968;
RX   PubMed=14555701;
RX   PubMed=14760100;
RX   PubMed=29045832;
WW   https://www.keatslab.org/myeloma-cell-lines/hmcl-characteristics
CC   From: Epstein J.; Myeloma and Transplantation Research Center, Arkansas Cancer Research Center; Little Rock; USA.
CC   Sequence variation: Gene deletion; HGNC; 12637; KDM6A; Zygosity=Homozygous (PubMed=29045832).
CC   Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ4 (CelloPub=CLPUB00604).
CC   Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (CelloPub=CLPUB00604).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
ST   Source(s): CCRID=1101HUM-PUMC000681
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D12S391: 18.3,22
ST   D13S317: 9,14
ST   D16S539: 11,12
ST   D18S51: 15
ST   D19S433: 13,14
ST   D21S11: 28,31.2
ST   D2S1338: 20,21
ST   D3S1358: 15,18
ST   D5S818: 12,13
ST   D6S1043: 19
ST   D7S820: 10,12
ST   D8S1179: 10,13
ST   FGA: 18,19,24
ST   Penta E: 7,15
ST   TH01: 6,7
ST   TPOX: 11,12
ST   vWA: 14,18
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_D523 ! ARP-1
OI   CVCL_D569 ! CAG
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 06-09-19; Last updated: 02-05-24; Version: 8
//
RX   CelloPub=CLPUB00604;
RA   Chow S.;
RT   "Targeted capture and sequencing of immunoglobulin rearrangements
RT   in multiple myeloma to enable detection of minimal residual disease.";
RL   Thesis MSc (2017), University of Toronto, Canada.
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York (2000).
//
RX   PubMed=8427968; DOI=10.1182/blood.V81.3.767.767;
RA   Ridley R.C., Xiao H.-Q., Hata H., Woodliff J., Epstein J.,
RA   Sanderson R.D.;
RT   "Expression of syndecan regulates human myeloma plasma cell adhesion
RT   to type I collagen.";
RL   Blood 81:767-774(1993).
//
RX   PubMed=14555701;
RA   Shammas M.A., Shmookler Reis R.J., Akiyama M., Koley H., Chauhan D.,
RA   Hideshima T., Goyal R.K., Hurley L.H., Anderson K.C., Munshi N.C.;
RT   "Telomerase inhibition and cell growth arrest by G-quadruplex
RT   interactive agent in multiple myeloma.";
RL   Mol. Cancer Ther. 2:825-833(2003).
//
RX   PubMed=14760100; DOI=10.1158/1078-0432.CCR-0793-03;
RA   Shammas M.A., Shmookler Reis R.J., Li C., Koley H., Hurley L.H.,
RA   Anderson K.C., Munshi N.C.;
RT   "Telomerase inhibition and cell growth arrest after telomestatin
RT   treatment in multiple myeloma.";
RL   Clin. Cancer Res. 10:770-776(2004).
//
RX   PubMed=29045832; DOI=10.1016/j.celrep.2017.09.078;
RA   Ezponda T., Dupere-Richer D., Will C.M., Small E.C., Varghese N.,
RA   Patel T., Nabet B., Popovic R., Oyer J., Bulic M., Zheng Y.-P.,
RA   Huang X.-X., Shah M.Y., Maji S., Riva A., Occhionorelli M., Tonon G.,
RA   Kelleher N.L., Keats J.J., Licht J.D.;
RT   "UTX/KDM6A loss enhances the malignant phenotype of multiple myeloma
RT   and sensitizes cells to EZH2 inhibition.";
RL   Cell Rep. 21:628-640(2017).
//